A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase

N/A

Condition

Body Composition

Weight Loss

Diabetes Mellitus, Type 2

Treatment

N/A

Clinical Study ID

TX322067

Ages 18-90
All Genders

Study Summary

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

Eligibility Criteria

Inclusion

Inclusion Criteria

Be 18+ years of age.
Diagnosed with Type 2 Diabetes for 6 months or longer.
Have a body mass index (BMI) ≥ 30 kg/m2.
Have an HbA1c 7% - 10.5%
Taking Metformin and on stable treatment for T2D for at least 90 days prior to screening.

Study Design

Study Description

Additional study details available by filling out the information below.

Connect with a study center

Headlands Research- AMCR Institute
Escondido, California 92025
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.